Cognition Therapeutics Inc
CGTX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001455365
No open-market purchases or sales by Cognition Therapeutics Inc insiders were filed in the last 90 days; 66 institutions reported holding it in 13F filings for Q2 2026, worth $26.0M in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding Cognition Therapeutics Inc changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Of which not filed for Q3 2025 | Q3 2025 | Change |
|---|---|---|---|---|
| Holders | 48 | 2 | 68 | +22 |
| Shares | 11.2M | 75.4K | 21.3M | +10.1M (+90.8%) |
| Value | $3.50M | $23.3K | $28.7M | +$25.2M (+726.8%) |
2 institutions that held it in Q2 2025 haven't filed for Q3 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (30)
Institutions that held Cognition Therapeutics Inc at the end of Q3 2025 but not at the end of Q2 2025.
Sold out (8)
Institutions that held Cognition Therapeutics Inc at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Acadian Asset Management LLC | 701,940 | $216.0K |
| CM Management, LLC | 250,000 | $77.5K |
| Kestra Advisory Services, LLC | 155,934 | $48.3K |
| Nwam LLC | 42,777 | $25.1K |
| Essex Financial Services, Inc. | 39,595 | $12.3K |
| Apella Capital, LLC | 11,200 | $6.48K |
| XTX Topco Ltd | 16,603 | $5.14K |
| Goldman Sachs Group Inc | 14,635 | $4.53K |
Not filed for Q3 2025 yet (2)
Institutions that held Cognition Therapeutics Inc at the end of Q2 2025 and haven't filed a 13F for Q3 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Northeast Financial Consultants Inc | 63,351 | $19.6K |
| Smith Anglin Financial, LLC | 12,000 | $3.72K |